HHS announces Medicare premium increase for Aduhelm will be adjusted in 2023

HHS announced that Medicare Part B premiums paid in 2022 should be lowered in 2023 to account for an overestimate in costs related to inclusion of Aduhelm within the Medicare program for reimbursement.
According to an HHS release, legal and operational hurdles prevented adjustments in Medicare premiums this year, prompting reductions in costs attributable to Aduhelm (aducanumab, Biogen) into Medicare premiums in 2023 to lower Part B premiums paid by Medicare beneficiaries.
The decision to lower premium payments arose after HHS received a report from CMS, which concluded that cost savings from

HHS announced that Medicare Part B premiums paid in 2022 should be lowered in 2023 to account for an overestimate in costs related to inclusion of Aduhelm within the Medicare program for reimbursement.
According to an HHS release, legal and operational hurdles prevented adjustments in Medicare premiums this year, prompting reductions in costs attributable to Aduhelm (aducanumab, Biogen) into Medicare premiums in 2023 to lower Part B premiums paid by Medicare beneficiaries.
The decision to lower premium payments arose after HHS received a report from CMS, which concluded that cost savings from